Effect of Abciximab Therapy in Patients Undergoing Coronary Angioplasty for Acute ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock
| Autor: | Francesco De Felice, Carmine Musto, Roberto Violini, Antonio Parma, Rosario Fiorilli, Francesco Tomassini, Andrea Gagnor, Ferdinando Varbella, Marco Stefano Nazzaro, Enrico Cerrato |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty Abciximab medicine.medical_treatment Myocardial Infarction Shock Cardiogenic Disease-Free Survival Immunoglobulin Fab Fragments Internal medicine medicine Humans cardiovascular diseases Myocardial infarction Angioplasty Balloon Coronary Aged Proportional Hazards Models Retrospective Studies Aged 80 and over Proportional hazards model business.industry Cardiogenic shock Hazard ratio Antibodies Monoclonal Percutaneous coronary intervention General Medicine Middle Aged medicine.disease Survival Rate Conventional PCI Cardiology Female Cardiology and Cardiovascular Medicine business TIMI Follow-Up Studies medicine.drug |
| Zdroj: | Circulation Journal. 79:1568-1574 |
| ISSN: | 1347-4820 1346-9843 |
| DOI: | 10.1253/circj.cj-15-0053 |
| Popis: | BACKGROUND The effect of abciximab on survival in patients with ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock (CS) undergoing primary percutaneous coronary intervention (PCI) is not clear. METHODS AND RESULTS: We evaluated outcome in 410 consecutive patients with STEMI and CS who underwent PCI treated without (n=123) or with (n=287) abciximab. The endpoint was survival at 1-year follow-up. The predictors of death at 1 year were also investigated. The groups with and without abciximab had similar survival at 1-year follow-up. Propensity score-adjusted Cox proportional hazards model identified age (adjusted hazard ratio [HR], 1.02; 95% confidence interval [95% CI]: 1.01-1.03, P=0.001), oro-tracheal intubation (HR, 1.49; 95% CI: 1.12-1.96, P=0.05), post-PCI TIMI flow grade 0-1 (HR, 2.08; 95% CI: 1.52-2.83, P=0.0001) but not abciximab use (HR, 1.08; 95% CI: 0.70-1.60, P=0.60) as independent predictors of death at 1-year follow-up. Cox adjusted 1-year survival rates were 42.8% and 51.6%, (P=0.56) in patients treated without vs. with abciximab, respectively. CONCLUSIONS Patients with STEMI complicated by CS undergoing PCI treated with or without abciximab have similar 1-year survival rates; age, final TIMI 0-1 and oro-tracheal intubation are predictors of death. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|